Figure 2.
Event-free survival of patients in the per-protocol group in the titration trial and the embedded randomised trial
(A) Event-free survival of the patients in the per-protocol group in the titration trial, for patients with adequate response without radiotherapy (blue) and patients with inadequate response scheduled for radiotherapy (red). (B) Event-free survival of the patients in the per-protocol group in the embedded randomisation trial who were treated with COPP (red) and COPDAC (blue). COPP=cyclophosphamide, vincristine, prednisone, and procarbazine. COPDAC=cyclophosphamide, vincristine, prednisone, and dacarbazine.